JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients
Chien, Tsu-Ming; Lu, Yen-Man; Geng, Jiun-Hung; Huang, Tsung-Yi; Ke, Hung-Lung; Huang, Chun-Nung; Li, Ching-Chia; Chou, Yii-Her; Wu, Wen-Jeng; Huang, Shu-Pin;
  PDF(new window)
 Abstract
Background: The prevalence of prostate cancer (PCa) has been increasing in recent years. Treatment strategies are largely based on the results of bone scan screening. Therefore, our aim was to investigate predictors of positive bone metastasis in newly diagnosed PCa patients. Materials and Methods: After extensive review, 336 consecutive patients newly diagnosed with PCa between April 2010 and November 2013 at our institution were enlisted in the study. Patients were divided into two groups according to bone scan results. Univariate analyses (Chi-square test for discrete variables and independent t-test for continuous variables) were applied to determine the potentially significant risk factors associated with distant bone metastasis. Binary logistic regression analyses were used to further investigate the influence of these factors on bone metastasis. Results: The patient mean age was (range: 48 to 94 years). The mean prostate specific antigen (PSA) level and biopsy Gleason score were and , respectively. The body mass index (BMI) for the series was . Sixty-four patients (19.0%) had a positive bone scan result. Patients with positive bone scan results had a significantly lower BMI ( vs. ; p
 Keywords
Prostate cancer;bone metastasis;prostate specific antigen;predictive actors;
 Language
English
 Cited by
 References
1.
Bashir MN, Ahmad MR, Malik A (2014). Risk factors of prostate cancer: a case-control study in Faisalabad, Pakistan. Asian Pac J Cancer Prev, 15, 10237-40.

2.
Briganti A, Passoni N, Ferrari M, et al (2010). When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol, 57, 551-8. crossref(new window)

3.
Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007). Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol, 178, S14-9. crossref(new window)

4.
Dennis ER, Jia X, Mezheritskiy IS, et al (2012). Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol, 30, 519-24. crossref(new window)

5.
Drzymalski DM, Oh WK, Werner L, et al (2010). Predictors of survival in patients with prostate cancer and spinal metastasis. presented at the 2009 joint spine section meeting. clinical article. J Neurosurg Spine, 13, 789-94. crossref(new window)

6.
Falchook AD, Salloum RG, Hendrix LH, Chen RC (2014). Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys, 89, 243-8. crossref(new window)

7.
Greene KL, Albertsen PC, Babaian RJ, et al (2009). Prostate specific antigen best practice statement: 2009 update. J Urol, 182, 2232-41. crossref(new window)

8.
Harada M, Iida M, Yamaguchi M, Shida K (1992). Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol, 324, 173-82. crossref(new window)

9.
He D, Wang M, Chen X, et al (2004). Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population. Urol, 63, 722-6. crossref(new window)

10.
Heidenreich A, Bastian PJ, Bellmunt J, et al (2014). European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol, 65, 124-37. crossref(new window)

11.
Hu MB, Liu SH, Jiang HW, Bai PD, Ding Q (2014). Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients. PLoS One, 9, 106677. crossref(new window)

12.
Imbriaco M, Larson SM, Yeung HW, et al (1998). A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res, 4, 1765-72.

13.
Isom-Batz G, Bianco FJ Jr, Kattan MW, et al (2005). Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol, 173, 1935-7. crossref(new window)

14.
Kosuda S, Yoshimura I, Aizawa T, et al (2002). Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer, 94, 964-72. crossref(new window)

15.
Lee N, Fawaaz R, Olsson CA, et al (2000). Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys, 48, 1443-6. crossref(new window)

16.
Logothetis CJ, Lin SH (2005). Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer, 5, 21-8. crossref(new window)

17.
Morgentaler A, Bruning CO 3rd, DeWolf WC (1996). Occult prostate cancer in men with low serum testosterone levels. JAMA, 276, 1904-6. crossref(new window)

18.
Nakashima J, Tachibana M, Ueno M, et al (1998). Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res, 4, 1743-8

19.
Nandeesha H (2009). Insulin: a novel agent in the pathogenesis of prostate cancer. Int Urol Nephrol, 41, 267-72. crossref(new window)

20.
National Comprehensive Cancer Network Guidelines (2014). Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

21.
Oesterling JE, Kumamoto Y, Tsukamoto T, et al (1995). Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol, 75, 347-53. crossref(new window)

22.
Ost P, Decaestecker K, Lambert B, et al (2014). Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate, 74, 297-305. crossref(new window)

23.
Pound CR, Partin AW, Eisenberger MA, et al (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281, 1591-7. crossref(new window)

24.
Sabbatini P, Larson SM, Kremer A, et al (1999). Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol, 17, 948-57. crossref(new window)

25.
Schweizer MT, Zhou XC, Wang H, et al (2013). Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol, 24, 2881-6. crossref(new window)

26.
Singh D, Yi WS, Brasacchio RA, et al (2004). Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys, 58, 3-10. crossref(new window)

27.
Soloway MS, Hardeman SW, Hickey D, et al (1988). Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61, 195-202. crossref(new window)

28.
Tanaka N, Fujimoto K, Shinkai T, et al (2011). Bone scan can be spared in asymptomatic prostate cancer patients with PSA of ${\leq}20$ ng/ml and Gleason score of ${\leq}6$ at the initial stage of diagnosis. Jpn J Clin Oncol, 41, 1209-13. crossref(new window)

29.
Young CY, Montgomery BT, Andrews PE, et al (1991). Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res, 51, 3748-52.